PerkinElmer has launched a new biomarker initiative that may lead the company down the path to diagnostics and clinical development, Mary Lopez, business leader for analytical proteomics at PerkinElmer, told ProteoMonitor this week.

“PerkinElmer is a tools company, but we are moving into the area of platforms and solutions,” Lopez said. “We are developing a platform for biomarker screening, and initially it will be a research platform. Whether we go into the clinical area is still something that is under discussion, but is not off the table.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

Sponsored by

This webinar will discuss an automated, high-throughput method of generating high-quality antigens and antibodies.